Track the Takeda Pharmaceutical Company Limited stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.5bn. The latest transaction was disclosed on 14 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Nicola Greenway. All data is accessible without an account.
16
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,437 of 29,062 companies
56.9
score / 100
Value
79
Quality
35
FCF yld·
Earn yld·
EV/EBITDA6.8x
ROE-2.3%
Gross mgn65%
Net mgn-3.4%
Debt/EBITDA6.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,319 shares@ US$16.7519100.0% of flowAmerican Depositary Shares (ADSs)SEC144:0001395064-26-000311
16 of 16 declarations
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, specializing in the research and development of innovative medicines. It focuses on therapeutic areas such as oncology, rare diseases, and gastrointestinal disorders.